rosiglitazone has been researched along with Ovarian Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, J; Liu, H; Ohno, Y; Wang, Z; Xu, C | 1 |
| Hu, J; Jing, X; Li, W; Su, P; Wang, X; Wu, X; Zhang, H; Zhang, X; Zhou, G | 1 |
| Apellániz-Ruiz, M; Bergmann, TK; Brøsen, K; Green, H; Ingelman-Sundberg, M; Johansson, I; Lee, MY; Rodríguez-Antona, C; Vikingsson, S | 1 |
| Carson, DD; Morgado, M | 1 |
| Peng, ZL; Ren, QC; Tan, X | 1 |
| Al-Alem, L; Curry, TE; Kilgore, MW; Southard, RC | 1 |
| Brard, L; Brodsky, AS; Fischer, A; Hillenmeyer, S; Kim, KK; Miller, DH; Raphael, BJ; Ritz, A; Singh, RK; Stuckey, A | 1 |
7 other study(ies) available for rosiglitazone and Ovarian Neoplasms
| Article | Year |
|---|---|
Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Phthalazines; Piperazines; Rosiglitazone; Tumor Suppressor Protein p53 | 2020 |
Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes.
Topics: Active Transport, Cell Nucleus; Anilides; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; beta Catenin; Cell Line, Tumor; Cell Nucleus; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Frizzled Receptors; Humans; Ovarian Neoplasms; Paclitaxel; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription, Genetic; Wnt Proteins | 2015 |
Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
Topics: Alleles; Amodiaquine; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Cytochrome P-450 CYP2C8; Dose-Response Relationship, Drug; Female; HEK293 Cells; Humans; Isoenzymes; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Risk Factors; Rosiglitazone; Substrate Specificity; Thiazolidinediones | 2015 |
PPARγ Modulation of Cytokine-Stimulated MUC16 (CA125) Expression in Breast and Ovarian Cancer-Derived Cells.
Topics: Anilides; Breast Neoplasms; CA-125 Antigen; Female; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; MCF-7 Cells; Membrane Proteins; Neoplasm Proteins; Ovarian Neoplasms; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2017 |
[Proliferation and apoptosis effect of rosiglitazone on human ovarian cancer cell line SKOV3].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; PPAR gamma; Proto-Oncogene Proteins c-myc; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2009 |
Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromans; Female; Gene Expression; Humans; Ovarian Neoplasms; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Troglitazone | 2011 |
Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Cluster Analysis; Ergocalciferols; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Transcriptome; Tumor Burden; Vitamins; Xenograft Model Antitumor Assays | 2011 |